The effects of various cytostatic drug regimens on the numbers of the individual white-cell types were studied retrospectively. 131 children with solid tumors were classified into six groups according to the type of tumor. All children within the same group received similar treatment. Differential counts were performed manually, as well as with the Hemalog D. The number of lymphocytes usually decreased rapidly after initial treatment and remained at the low level throughout the period of therapy. In the majority of the children the lymphocyte count became normal between 1 and 12 months after cessation of therapy. In contrast, granulocyte and monocyte counts were not affected in some children, whereas in other children the numbers of these cell types decreased. When there was a decrease in number, the number was soon restored and, in nearly all children, before the end of therapy.

Keywords:
Antineoplastic therapy, Automated cytochemistry, Childhood cancer, Differential leukocyte count, Hemalog D
This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.